Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus

This publication has 38 references indexed in Scilit:

• Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors1In conducting the research described in this report, the investigators adhered to the Guide for Care and Use of Laboratory Animals, as promulgated by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council. The facilities are fully accredited by the American Association for Accreditation of Laboratory Animal Care. The views of the authors do not purport to reflect the positions of the Department of the Army or the Department of Defense.1
  Vaccine, 1999
• Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine
  Vaccine, 1998
• Improved Protection against Venezuelan Equine Encephalitis by Genetic Engineering of a Recombinant Vaccinia Virus
  Viral Immunology, 1998
• A simple device for the exposure of animals to infectious microorganisms by the airborne route
  Epidemiology and Infection, 1997
• Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine
  Vaccine, 1996
• Enhancement of protective immune responses to Venezuelan equine encephalitis (VEE) virus with microencapsulated vaccine
  Vaccine, 1995
• Recombinant Vaccinia/Venezuelan Equine Encephalitis (VEE) Virus Expresses VEE Structural Proteins
  Journal of General Virology, 1988
• TC‐83 Venezuelan equine encephalitis vaccine exposure during pregnancy
  Teratology, 1987
• Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells
  Cell, 1979
• Immunization with Live Types 7 and 4 Adenovirus Vaccines. II. Antibody Response and Protective Effect against Acute Respiratory Disease Due to Adenovirus Type 7
  The Journal of Infectious Diseases, 1971